[go: up one dir, main page]

AR031714A1 - Composiciones farmaceuticas que contienen un compuesto con sistema para entrega de droga - Google Patents

Composiciones farmaceuticas que contienen un compuesto con sistema para entrega de droga

Info

Publication number
AR031714A1
AR031714A1 ARP010103302A ARP010103302A AR031714A1 AR 031714 A1 AR031714 A1 AR 031714A1 AR P010103302 A ARP010103302 A AR P010103302A AR P010103302 A ARP010103302 A AR P010103302A AR 031714 A1 AR031714 A1 AR 031714A1
Authority
AR
Argentina
Prior art keywords
spacer
compound
linked
amino
carboxyl group
Prior art date
Application number
ARP010103302A
Other languages
English (en)
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of AR031714A1 publication Critical patent/AR031714A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmacéutica que contiene un compuesto con sistema de entrega de droga (DDS), donde un derivado de polisacárido que tiene un grupo carboxilo- es ligado a un derivado de camptotecina por medio de una cadena peptídica (un espaciador) o sin mediacion de espaciador, y un azucar o alcohol de azucar que asegura la estabilidad de conservacion del compuesto. Una composicion farmacéutica que contiene un compuesto donde un derivado de û polisacárido que tiene un grupo carboxilo es ligado a (1S, 9S)-1-amino-9-etil-5-fluoro-2,3-dihidro-9-hidroxi-4-metil-1H, 12H-benzo [de] pirano[3', 4':6,7] indolizino[1,2-b] quinolina-10-13(9H, 15H)-diona por medio de un espaciador que comprende un aminoácido o espaciador que consiste de 2 a 8 aminoácidos ligados entre sí por medio de enlaces peptídicos, o un compuesto donde un derivado de polisacárido que tiene un grupo carboxílico es ligado a (1S, 9S)-1-amino-9-etil-5-fluoro-2,3-dihidro-9-hidroxi-4-metil-1H, 12H-benzo[de]pirano[3', 4':6,7] indolizino [1,2-b]quinolina-10-13(9H, 15H-diona sin mediacion de un espaciador y una o más azucares o alcoholes de azucar seleccionados del grupo formado por maltosa, glucosa, lactosa, trehalosa, sacarosa, mannitol, inositol, galactosa, ribosa, xilosa, mannosa, sucrosa, celobiosa, rafinosa y maltotriosa. La composicion incluye, si es necesario, una sustancia ajustadora de pH y luego se seca por congelacion. El polisacárido que tiene un grupo carboxilo es preferentemente un polialcohol-carboxi (alquilo C1-4) dextrano. El espaciador consiste preferentemente de aminoácidos representados por la secuencia de aminoácidos (extremo N) ûGly-Gly-Phe-Gly-(extremo C).
ARP010103302A 2000-07-13 2001-07-12 Composiciones farmaceuticas que contienen un compuesto con sistema para entrega de droga AR031714A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000213083 2000-07-13

Publications (1)

Publication Number Publication Date
AR031714A1 true AR031714A1 (es) 2003-10-01

Family

ID=18708899

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103302A AR031714A1 (es) 2000-07-13 2001-07-12 Composiciones farmaceuticas que contienen un compuesto con sistema para entrega de droga

Country Status (12)

Country Link
US (1) US6815435B2 (es)
EP (1) EP1308171A1 (es)
KR (1) KR20030023697A (es)
CN (1) CN1556712A (es)
AR (1) AR031714A1 (es)
AU (1) AU2001271037A1 (es)
BR (1) BR0112417A (es)
CA (1) CA2415922A1 (es)
MX (1) MXPA03000387A (es)
NO (1) NO20030139L (es)
RU (1) RU2003100532A (es)
WO (1) WO2002005855A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000734A1 (fr) * 2000-06-29 2002-01-03 Daiichi Pharmaceutical Co., Ltd. Compose dds et son procede de preparation
TWI320713B (es) * 2001-06-01 2010-02-21 Neochemir Inc
TW200306314A (en) * 2002-04-16 2003-11-16 Tanabe Seiyaku Co Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation
CN100366261C (zh) * 2002-12-10 2008-02-06 田中雅也 皮肤外用材料及使用其的外用止痒剂和去皱用品
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
AU2013263795B2 (en) * 2010-03-29 2015-09-17 Ferring B.V. A fast dissolving pharmaceutical composition
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
ES2643087T3 (es) * 2010-03-29 2017-11-21 Ferring B.V. Composición farmacéutica de disolución rápida
CN103781467B (zh) 2011-09-16 2016-08-31 辉凌公司 一种快速溶解药物组合物
BR122021014396B1 (pt) 2012-10-11 2022-07-05 Daiichi Sankyo Company, Limited Compostos intermediários ligantes de fármacos, e ligante
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
KR102535900B1 (ko) 2013-12-25 2023-05-26 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
BR112016013482B1 (pt) 2014-01-31 2022-04-19 Daiichi Sankyo Company, Limited Conjugado de anticorpo anti-her2-fármaco, fármacos antitumor e/ou anticâncer e composição farmacêutica
KR102445502B1 (ko) 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
ES2754348T3 (es) 2014-04-10 2020-04-17 Daiichi Sankyo Co Ltd Conjugado de (anticuerpo anti-HER2)-fármaco
AU2015369185B2 (en) 2014-12-26 2020-10-22 Nippon Kayaku Kabushiki Kaisha Pharmaceutical preparation of camptothecin-containing polymer derivative
IL290959B2 (en) 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Preparations containing antibody-drug conjugates and methods for their production
JP6735759B2 (ja) 2015-09-03 2020-08-05 日本化薬株式会社 カンプトテシン類高分子誘導体を含有する医薬組成物
JP6797182B2 (ja) 2016-03-01 2020-12-09 日本化薬株式会社 カンプトテシン類高分子誘導体を含有する医薬製剤
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
SG11202000997YA (en) 2017-08-31 2020-03-30 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
US11318212B2 (en) 2017-08-31 2022-05-03 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
CN112351999A (zh) 2018-05-18 2021-02-09 第一三共株式会社 抗-muc1抗体-药物缀合物
TWI822822B (zh) 2018-07-31 2023-11-21 日商第一三共股份有限公司 抗體-藥物結合物之用途
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
WO2021007435A1 (en) 2019-07-10 2021-01-14 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
JPS61165322A (ja) * 1985-01-14 1986-07-26 Microbial Chem Res Found スパガリン類の注射用凍結乾燥製剤
EP0857484A4 (en) 1995-09-13 2000-12-06 Nippon Shinyaku Co Ltd PGE1- FREEZING DRIED PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
PL328309A1 (en) * 1996-02-19 1999-01-18 Nycomed Imaging As Thermally stabilised contrast medium
AU2034097A (en) * 1996-03-19 1997-10-10 Morgan Crucible Company Plc, The A conduit
JPH10212241A (ja) 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6583164B1 (en) 1998-09-29 2003-06-24 Takeda Chemical Industries, Ltd. Antimycotic drug composition

Also Published As

Publication number Publication date
EP1308171A1 (en) 2003-05-07
KR20030023697A (ko) 2003-03-19
WO2002005855A1 (fr) 2002-01-24
NO20030139L (no) 2003-03-13
NO20030139D0 (no) 2003-01-10
MXPA03000387A (es) 2003-09-22
CA2415922A1 (en) 2002-01-24
CN1556712A (zh) 2004-12-22
AU2001271037A1 (en) 2002-01-30
US6815435B2 (en) 2004-11-09
US20030148931A1 (en) 2003-08-07
RU2003100532A (ru) 2004-07-20
BR0112417A (pt) 2003-07-01

Similar Documents

Publication Publication Date Title
AR031714A1 (es) Composiciones farmaceuticas que contienen un compuesto con sistema para entrega de droga
CA2272245A1 (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
ES2566797T3 (es) Compuestos de polímero de polialquileno y usos de éstos
RU2008142359A (ru) Композиция человеческого моноклонального антитела к igf-1r
WO2003009817A3 (en) Stable lyophilized pharmaceutical formulation of igg antibodies
US20020147138A1 (en) Enzyme-activated anti-tumor prodrug compounds
Cohen et al. Enhancement of the antitumor effects of 1, 3-bis (2-chloroethyl)-1-nitrosourea and cyclophosphamide by vitamin A
CA2223063A1 (en) Drug delivery enhancement via modified saponins
DE19926154A1 (de) Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE60022664D1 (de) Herstellungsverfahren von submikrometerwirkstoffpartikeln
AR017120A1 (es) Composiciones farmaceuticas que contienen proteina plasmatica.
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
PE58998A1 (es) Terapia combinada para la osteoporosis
FI3484446T3 (fi) Vasta-ainekoostumuksia
ATE289801T1 (de) Verabreichungssystem für wasserunlösliche arzneistoffe
BR0112287A (pt) Composto dds e seu método de preparação
MXPA04000028A (es) Formulacion farmaceutica para la administracion intramuscular de fulvestrant.
KR100700963B1 (ko) 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제
CN101743020A (zh) 低粘度蒽环制剂
JPH06505755A (ja) 重合体誘導体結合アンスラサイクリン配糖体を含有する医薬組成物及びその製造方法
ECSP055960A (es) Formulaciones parenterales de un péptido para el tratamiento de lupus sistémico eritematoso
CA2389302A1 (en) Delivery of proteins across polar epithelial cell layers
JPH10502616A (ja) Ｄｘ−５２−１化合物の安定化法及びその凍結乾燥組成物
AR030207A1 (es) Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
AR014884A1 (es) Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure